Clinical Trials
82 trialsA Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
A Study of DXC014 in Patients With Advanced Solid Tumors.
Hangzhou DAC Biotechnology Co., Ltd.
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
HYPOGRYPHE
Wake Forest University Health Sciences
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Radiopharm Theranostics, Ltd
Tamarack
MacroGenics
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Study of GV20-0251 in Participants With Solid Tumor Malignancies
GV20 Therapeutics
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
AM-003
University of Virginia
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
START-001
Marengo Therapeutics, Inc.
PRESERVE-001
OncoC4, Inc.
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
ACROPOLI
SOLTI Breast Cancer Research Group
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Seagen Inc.
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
National Cancer Institute (NCI)
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
AstraZeneca
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
JAVELIN Medley
Pfizer
DUET-3
Xencor, Inc.
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
Centre hospitalier de l'Université de Montréal (CHUM)
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
TORCH
University of Florida
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
DUET-1-02
Xencor, Inc.
DUET-4
Xencor, Inc.
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
DUET-2
Xencor, Inc.
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
A Study of PLX2853 in Advanced Malignancies.
Opna Bio LLC
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
AbbVie
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
AbbVie
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation